Merck KGaA: PharmaVitae ReportIntroductionThis analysis examines the historical and forecast performance for Merck KGaA in...
StrengthsWeaknessesOpportunitiesThreatsSTRATEGIC INSIGHTKey findingsStrategic restructureErbitux and Serono acquisition re...
FINANCIAL ANALYSISReconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales,...
Table: Key product sales ($m), 2010–16Table: Erbitux: overviewTable: Erbitux: sales forecast ($m), 2010–16Table: Rebif: ov...
About Us:ReportsnReports is an online library of over 100,000+ market research reports and in-depthmarket research studies...
Upcoming SlideShare
Loading in …5
×

Merck KGaA: PharmaVitae Report

658 views

Published on

Datamonitor’s “Merck KGaA: PharmaVitae Report” is now available at ReportsnReports.com.

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
658
On SlideShare
0
From Embeds
0
Number of Embeds
4
Actions
Shares
0
Downloads
5
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Merck KGaA: PharmaVitae Report

  1. 1. Merck KGaA: PharmaVitae ReportIntroductionThis analysis examines the historical and forecast performance for Merck KGaA in theprescription pharmaceutical sector. The profile encompasses global company strategy, portfolioand pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts forkey drugs.Features and benefits Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source. Gain insight into Merck KGaAs strategic outlook across the next 6 years.HighlightsStrategic insight into the prospects for Merck KGaA report over the next six years. Pickingout key strengths, weaknesses, opportunities and threats and evaluating the companysprescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.Table Of ContentsABOUT THIS REPORTPharmaVitae Explorer databaseChapter structureStrategic insightCompany introductionSales analysisFinancial analysisProduct analysisData sourcingAnalyst consensusEXECUTIVE SUMMARYKey findingsMerck KGaA prescription pharma sales outlookMerck KGaA financial outlookKey developments(Untitled sub-section)SWOT analysis
  2. 2. StrengthsWeaknessesOpportunitiesThreatsSTRATEGIC INSIGHTKey findingsStrategic restructureErbitux and Serono acquisition rejuvenate branded pharmaceuticals business…and diversify Merck KGaA’s portfolio to improve long-term prospectsRestructuring bolsters financial performanceCOMPANY INTRODUCTIONKey findingsBackgroundKey corporate developmentsM&A history(Untitled sub-section)Acquisition of MilliporeCurrent corporate structurePharmaceuticalsChemicalsSALES ANALYSISKey findingsPrescription pharmaceutical sales and growth rate analysis, 2004–16Product analysisProduct analysis, 2004–10Product analysis, 2010–16Therapy area analysisGeographic analysisLaunch/core/expiry analysisExplanation of launch/core/expiry analysisLaunch analysis, 2010–16Core analysis, 2010–16Expiry analysis, 2010–16Launch/core/expiry configuration, 2010–16Molecule type analysisExternalization analysis
  3. 3. FINANCIAL ANALYSISReconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2004–10Operating costs and profit analysisOperating costs and profit analysis, 2004–10Operating cost ratio and profit margin analysis, 2004–10Operating cost ratio and profit margin analysis, 2010–16Operating costs and profit analysis, 2010–16PRODUCT ANALYSISOverviewErbituxRebifMerck KGaA pipeline overviewAPPENDIXReferencesDatamonitor reportsExchange ratesLIST OF TABLESTable: Merck KGaA – key product overview ($m), 2010–16Table: Merck KGaA’s financial performance ($m), 2010–16Table: Merck KGaA product portfolio overview ($m), 2004–10Table: Merck KGaA product portfolio overview ($m), 2010–16Table: Merck KGaA prescription pharmaceutical sales, by therapy area ($m), 2010–16Table: Merck KGaA prescription pharmaceutical sales, by geographic region ($m), 2010–16Table: Merck KGaA launch portfolio overview ($m), 2010–16Table: Merck KGaA core portfolio overview ($m), 2010–16Table: Merck KGaA expiry portfolio overview ($m), 2010–16Table: Merck KGaA prescription pharmaceutical sales, by molecule type ($m), 2010–16Table: Merck KGaA prescription pharmaceutical sales, by source ($m), 2010–16Table: Total Merck KGaA sales, by business unit ($m), 2004–10Table: Merck KGaA operating revenues, costs, and profit ($m), 2004–10Table: Merck KGaA operating cost ratios and profit margin (as a percentage of total revenues),2004–10Table: Merck KGaA operating cost ratios and profit margin (as a percentage of total revenues),2010–16Table: Merck KGaA operating revenues, costs, and profit ($m), 2010–16
  4. 4. Table: Key product sales ($m), 2010–16Table: Erbitux: overviewTable: Erbitux: sales forecast ($m), 2010–16Table: Rebif: overviewTable: Rebif: sales forecast ($m), 2010–16Table: Merck KGaA’s R&D pipelineTable: Exchange rates, 2011LIST OF FIGURESFigure: The PharmaVitae ExplorerFigure: Merck KGaA prescription pharmaceutical performance, sales ($m) and growth rate(%), 2004–16Figure: Merck KGaA operating revenues, costs, and profit ($m), 2004–16Figure: Merck KGaA SWOT analysisFigure: Merck KGaA’s (pre-Serono acquisition) biologics focus (percentage of pharmaceuticalsales), 2004 and 2007Figure: Merck KGaA’s therapeutic focus (percentage of branded ethical sales), 2004, 2010, and2016Figure: Merck KGaA’s revenue split, 2004–16Figure: Current corporate structureFigure: Merck KGaA prescription pharmaceutical performance, sales ($m) and growth rate(%), 2004–16Figure: Merck KGaA’s key product sales ($m), 2004–16Figure: Merck KGaA key sales growth drivers and resistors ($m), 2004–10Figure: Merck KGaA key sales growth drivers and resistors ($m), 2010–16Figure: Merck KGaA prescription pharmaceutical sales, by therapy area ($m), 2004–16Figure: Merck KGaA prescription pharmaceutical sales, by geographic region ($m), 2004–16Figure: Merck KGaA launch/core/expiry configuration ($m), 2010–16Figure: Merck KGaA prescription pharmaceutical sales, by molecule type ($m), 2004–16Figure: Merck KGaA prescription pharmaceutical sales, by source ($m), 2004–16Figure: Merck KGaA operating revenues, costs, and profit ($m), 2004–16Figure: Erbitux sales, by geographic region ($m), 2004–16Figure: Rebif sales, by geographic region ($m), 2004–16Figure: Merck KGaA’s pipeline, by therapy area
  5. 5. About Us:ReportsnReports is an online library of over 100,000+ market research reports and in-depthmarket research studies & analysis of over 5000 micro markets. We provide 24/7 online andoffline support to our customers. Get in touch with us for your needs of market research reports.Follow us on Twitter: http://twitter.com/marketsreportsContact:Mr.Priyank7557 Rambler road,Suite727,Dallas,TX75231Tel: + 1 888 391 5441E-mail: sales@reportsandreports.comhttp://www.reportsnreports.comVisit our Market Research Blog

×